The target landscape of clinical kinase drugs

Science

Volumn 358, Issue 6367, 2017, Pages

  Klaeger, Susan ^a,b   Heinzlmeir, Stephanie ^a,b   Wilhelm, Mathias ^a   Polzer, Harald ^b,c   Vick, Binje ^b,d   Koenig, Paul Albert ^a   Reinecke, Maria ^a,b   Ruprecht, Benjamin ^a   Petzoldt, Svenja ^a,b   Meng, Chen ^a   Zecha, Jana ^a,b   Reiter, Katrin ^b,c   Qiao, Huichao ^a   Helm, Dominic ^a   Koch, Heiner ^a,b   Schoof, Melanie ^a   Canevari, Giulia ^e   Casale, Elena ^e   Re Depaolini, Stefania ^e   Feuchtinger, Annette ^d   Wu, Zhixiang ^a   Schmidt, Tobias ^a   Rueckert, Lars ^f   Becker, Wilhelm ^f   Huenges, Jan ^f   Garz, Anne Kathrin ^b,g   Gohlke, Bjoern Oliver ^b,h   Zolg, Daniel Paul ^a   Kayser, Gian ⁱ   Vooder, Tonu ^j,k,l   Preissner, Robert ^b,h   Hahne, Hannes ^a   Tõnisson, Neeme ^k,l   Kramer, Karl ^a   Götze, Katharina ^b,g   Bassermann, Florian ^b,g   Schlegl, Judith ^m   Ehrlich, Hans Christian ^f   Aiche, Stephan ^f   Walch, Axel ^d   Greif, Philipp A ^b,c   Schneider, Sabine ^a,n   Felder, Eduard Rudolf ^e   Ruland, Juergen ^a,b   Médard, Guillaume ^a   Jeremias, Irmela ^b,c,d   Spiekermann, Karsten ^b,c   Kuster, Bernhard ^a,b,n   more..

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e NERVIANO MEDICAL SCIENCES   (Italy)

^f TUM ^*  (Germany)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

^j Center of Thoracic Surgery   (Germany)

^k UNIVERSITY OF TARTU   (Estonia)

^l TARTU UNIVERSITY HOSPITAL   (Estonia)

^m SAP RESEARCH   (Germany)

ⁿ Munich Center for Integrated Protein Science   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; CABOZANTINIB; FLT3 LIGAND; GOLVATINIB; INTERLEUKIN 10; PHOSPHOTRANSFERASE INHIBITOR; TUMOR NECROSIS FACTOR; ANTINEOPLASTIC AGENT; CD135 ANTIGEN; CYTOKINE; FLT3 PROTEIN, HUMAN; MELK PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; SALT-INDUCIBLE KINASE-2, HUMAN;

BIOMARKER; CANCER; DRUG; DRUG DEVELOPMENT; INHIBITOR; PROTEOMICS; RESEARCH WORK;

ARTICLE; MASS SPECTROMETRY; PHOSPHOPROTEOMICS; PRIORITY JOURNAL; PROTEOMICS; ACUTE MYELOID LEUKEMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; DRUG SCREENING; ENZYMOLOGY; HUMAN; LUNG TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOKINES; DRUG DISCOVERY; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; LUNG NEOPLASMS; MICE; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEOMICS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85036597195     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aan4368     Document Type: Article

References (88)

1. P. Wu, T. E. Nielsen, M. H. Clausen, FDA-approved small-molecule kinase inhibitors. Trends Pharmacol. Sci. 36, 422–439 (2015). doi: 10.1016/j.tips.2015.04.005; pmid: 25975227
2. D. Fabbro, S. W. Cowan-Jacob, H. Moebitz, Ten things you should know about protein kinases: IUPHAR review 14. Br. J. Pharmacol. 172, 2675–2700 (2015). doi: 10.1111/bph.13096; pmid: 25630872
3. M. W. Karaman et al., A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127–132 (2008). doi: 10.1038/nbt1358; pmid: 18183025
4. Y. Gao et al., A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem. J. 451, 313–328 (2013). doi: 10.1042/BJ20121418; pmid: 23398362
5. M. I. Davis et al., Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1046–1051 (2011). doi: 10.1038/nbt.1990; pmid: 22037378
6. T. Anastassiadis, S. W. Deacon, K. Devarajan, H. Ma, J. R. Peterson, Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1039–1045 (2011). doi: 10.1038/nbt.2017; pmid: 22037377
7. J. Bain et al., The selectivity of protein kinase inhibitors: A further update. Biochem. J. 408, 297–315 (2007). doi: 10.1042/BJ20070797; pmid: 17850214
8. M. A. Fabian et al., A small molecule–kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329–336 (2005). doi: 10.1038/nbt1068; pmid: 15711537
9. S. P. Davies, H. Reddy, M. Caivano, P. Cohen, Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95–105 (2000). doi: 10.1042/bj3510095; pmid: 10998351
10. J. M. Elkins et al., Comprehensive characterization of the Published Kinase Inhibitor Set. Nat. Biotechnol. 34, 95–103 (2016). doi: 10.1038/nbt.3374; pmid: 26501955
11. J. T. Metz et al., Navigating the kinome. Nat. Chem. Biol. 7, 200–202 (2011). doi: 10.1038/nchembio.530; pmid: 21336281
12. HMS LINCS Database, http://lincs.hms.harvard.edu/db/(2016).
13. M. Bantscheff et al., Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035–1044 (2007). doi: 10.1038/nbt1328; pmid: 17721511
14. G. Médard et al., Optimized chemical proteomics assay for kinase inhibitor profiling. J. Proteome Res. 14, 1574–1586 (2015). doi: 10.1021/pr5012608; pmid: 25660469
15. M. Wilhelm et al., Mass-spectrometry-based draft of the human proteome. Nature 509, 582–587 (2014). doi: 10.1038/nature13319; pmid: 24870543
16. M. P. Patricelli et al., In situ kinase profiling reveals functionally relevant properties of native kinases. Chem. Biol. 18, 699–710 (2011). doi: 10.1016/j.chembiol.2011.04.011; pmid: 21700206
17. J. J. Sutherland, C. Gao, S. Cahya, M. Vieth, What general conclusions can we draw from kinase profiling data sets? Biochim. Biophys. Acta 1834, 1425–1433 (2013). doi: 10.1016/j.bbapap.2012.12.023; pmid: 23333421
18. A. F. Rudolf, T. Skovgaard, S. Knapp, L. J. Jensen, J. Berthelsen, A comparison of protein kinases inhibitor screening methods using both enzymatic activity and binding affinity determination. PLOS ONE 9, e98800 (2014). doi: 10.1371/journal.pone.0098800; pmid: 24915177
19. P. P. Graczyk, Gini coefficient: A new way to express selectivity of kinase inhibitors against a family of kinases. J. Med. Chem. 50, 5773–5779 (2007). doi: 10.1021/jm070562u; pmid: 17948979
20. J. C. M. Uitdehaag, G. J. R. Zaman, A theoretical entropy score as a single value to express inhibitor selectivity. BMC Bioinformatics 12, 94 (2011). doi: 10.1186/1471-2105-12-94; pmid: 21486481
21. A. C. Cheng, J. Eksterowicz, S. Geuns-Meyer, Y. Sun, Analysis of kinase inhibitor selectivity using a thermodynamics-based partition index. J. Med. Chem. 53, 4502–4510 (2010). doi: 10.1021/jm100301x; pmid: 20459125
22. S. Knapp et al., A public-private partnership to unlock the untargeted kinome. Nat. Chem. Biol. 9, 3–6 (2013). doi: 10.1038/nchembio.1113; pmid: 23238671
23. A. J. Kooistra et al., KLIFS: A structural kinase-ligand interaction database. Nucleic Acids Res. 44, D365–D371 (2016). doi: 10.1093/nar/gkv1082; pmid: 26496949
24. Z. Zhao et al., Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? ACS Chem. Biol. 9, 1230–1241 (2014). doi: 10.1021/cb500129t; pmid: 24730530
25. J. F. Ohren et al., Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11, 1192–1197 (2004). doi: 10.1038/nsmb859; pmid: 15543157
26. A. P. Bento et al., The ChEMBL bioactivity database: An update. Nucleic Acids Res. 42, D1083–D1090 (2014). doi: 10.1093/nar/gkt1031; pmid: 24214965
27. A. Fauster et al., A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis. Cell Death Dis. 6, e1767 (2015). doi: 10.1038/cddis.2015.130; pmid: 25996294
28. K. Clark et al., Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc. Natl. Acad. Sci. U.S.A. 109, 16986–16991 (2012). doi: 10.1073/pnas.1215450109; pmid: 23033494
29. J. Ozanne, A. R. Prescott, K. Clark, The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases. Biochem. J. 465, 271–279 (2015). doi: 10.1042/BJ20141165; pmid: 25351958
30. T. S. Gujral, L. Peshkin, M. W. Kirschner, Exploiting polypharmacology for drug target deconvolution. Proc. Natl. Acad. Sci. U.S.A. 111, 5048–5053 (2014). doi: 10.1073/pnas.1403080111; pmid: 24707051
31. A. C. Peterson, J. D. Russell, D. J. Bailey, M. S. Westphall, J. J. Coon, Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol. Cell. Proteomics 11, 1475–1488 (2012). doi: 10.1074/mcp.O112.020131; pmid: 22865924
32. S. Gallien et al., Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer. Mol. Cell. Proteomics 11, 1709–1723 (2012). doi: 10.1074/mcp.O112.019802; pmid: 22962056
33. E. Ardini et al., The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol. Oncol. 8, 1495–1507 (2014). doi: 10.1016/j.molonc.2014.06.001; pmid: 24962792
34. A. Vaishnavi et al., Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat. Med. 19, 1469–1472 (2013). doi: 10.1038/nm.3352; pmid: 24162815
35. P. J. Cook et al., Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target. Nat. Commun. 8, 15987 (2017). doi: 10.1038/ncomms15987; pmid: 28695888
36. L. Tang et al., Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. J. Biol. Chem. 280, 31220–31229 (2005). doi: 10.1074/jbc.M500805200; pmid: 15985434
37. J. A. Winger, O. Hantschel, G. Superti-Furga, J. Kuriyan, The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2). BMC Struct. Biol. 9, 7 (2009). doi: 10.1186/1472-6807-9-7; pmid: 19236722
38. S. Klaeger et al., Chemical proteomics reveals ferrochelatase as a common off-target of kinase inhibitors. ACS Chem. Biol. 11, 1245–1254 (2016). doi: 10.1021/acschembio.5b01063; pmid: 26863403
39. M. M. Savitski et al., Tracking cancer drugs in living cells by thermal profiling of the proteome. Science 346, 1255784 (2014). doi: 10.1126/science.1255784; pmid: 25278616
40. C. Borgo et al., Protein kinase CK2 potentiates translation efficiency by phosphorylating eIF3j at Ser127. Biochim. Biophys. Acta 1853, 1693–1701 (2015). doi: 10.1016/j.bbamcr.2015.04.004; pmid: 25887626
41. H. Koch et al., Phosphoproteome profiling reveals molecular mechanisms of growth-factor-mediated kinase inhibitor resistance in EGFR-overexpressing cancer cells. J. Proteome Res. 15, 4490–4504 (2016). doi: 10.1021/acs.jproteome.6b00621; pmid: 27794612
42. P. Mertins et al., Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55–62 (2016). doi: 10.1038/nature18003; pmid: 27251275
43. Y. Li et al., Network-based approach identified cell cycle genes as predictor of overall survival in lung adenocarcinoma patients. Lung Cancer 80, 91–98 (2013). doi: 10.1016/j.lungcan.2012.12.022; pmid: 23357462
44. A. Lin, C. J. Giuliano, N. M. Sayles, J. M. Sheltzer, CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials. eLife 6, e24179 (2017). doi: 10.7554/eLife.24179; pmid: 28337968
45. H.-T. Huang et al., MELK is not necessary for the proliferation of basal-like breast cancer cells. eLife 6, e26693 (2017). doi: 10.7554/eLife.26693; pmid: 28926338
46. S. Heinzlmeir et al., Chemical proteomics and structural biology define EPHA2 inhibition by clinical kinase drugs. ACS Chem. Biol. 11, 3400–3411 (2016). doi: 10.1021/acschembio.6b00709; pmid: 27768280
47. E. Buchdunger et al., Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295, 139–145 (2000). pmid: 10991971
48. F. M. Yakes et al., Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther. 10, 2298–2308 (2011). doi: 10.1158/1535-7163.MCT-11-0264; pmid: 21926191
49. C. Choudhary et al., Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol. Cell 36, 326–339 (2009). doi: 10.1016/j.molcel.2009.09.019; pmid: 19854140
50. J.-W. Lu et al., Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD). Cancer Lett. 376, 218–225 (2016). doi: 10.1016/j.canlet.2016.04.004; pmid: 27060207
51. H. Hahne et al., DMSO enhances electrospray response, boosting sensitivity of proteomic experiments. Nat. Methods 10, 989–991 (2013). doi: 10.1038/nmeth.2610; pmid: 23975139
52. J. Cox, M. Mann, MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372 (2008). doi: 10.1038/nbt.1511; pmid: 19029910
53. J. Cox et al., Andromeda: A peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794–1805 (2011). doi: 10.1021/pr101065j; pmid: 21254760
54. J. Cox et al., Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell. Proteomics 13, 2513–2526 (2014). doi: 10.1074/mcp.M113.031591; pmid: 24942700
55. C. Ritz, F. Baty, J. C. Streibig, D. Gerhard, Dose-response analysis using R. PLOS ONE 10, e0146021 (2015). doi: 10.1371/ journal.pone.0146021; pmid: 26717316
56. S. Lemeer, C. Zörgiebel, B. Ruprecht, K. Kohl, B. Kuster, Comparing immobilized kinase inhibitors and covalent ATP probes for proteomic profiling of kinase expression and drug selectivity. J. Proteome Res. 12, 1723–1731 (2013). doi: 10.1021/pr301073j; pmid: 23495751
57. H. Thorvaldsdóttir, J. T. Robinson, J. P. Mesirov, Integrative Genomics Viewer (IGV): High-performance genomics data visualization and exploration. Brief. Bioinform. 14, 178–192 (2013). doi: 10.1093/bib/bbs017; pmid: 22517427
58. J. T. Robinson et al., Integrative genomics viewer. Nat. Biotechnol. 29, 24–26 (2011). doi: 10.1038/nbt.1754; pmid: 21221095
59. B. Ruprecht et al., Comprehensive and reproducible phosphopeptide enrichment using iron immobilized metal ion affinity chromatography (Fe-IMAC) columns. Mol. Cell. Proteomics 14, 205–215 (2015). doi: 10.1074/mcp.M114.043109; pmid: 25394399
60. J. Rappsilber, M. Mann, Y. Ishihama, Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat. Protoc. 2, 1896–1906 (2007). doi: 10.1038/nprot.2007.261; pmid: 17703201
61. B. MacLean et al., Skyline: An open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966–968 (2010). doi: 10.1093/bioinformatics/btq054; pmid: 20147306
62. A. M. Gholami et al., Global proteome analysis of the NCI-60 cell line panel. Cell Rep. 4, 609–620 (2013). doi: 10.1016/j.celrep.2013.07.018; pmid: 23933261
63. W. Kabsch, Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr. D Biol. Crystallogr. 66, 133–144 (2010). doi: 10.1107/S0907444909047374; pmid: 20124693
64. W. Kabsch, XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132 (2010). doi: 10.1107/S0907444909047337; pmid: 20124692
65. K. Diederichs, P. A. Karplus, Better models by discarding data?. Acta Crystallogr. D Biol. Crystallogr. 69, 1215–1222 (2013). doi: 10.1107/S0907444913001121; pmid: 23793147
66. P. Evans, Resolving some old problems in protein crystallography. Science 336, 986–987 (2012). doi: 10.1126/science.1222162; pmid: 22628641
67. P. A. Karplus, K. Diederichs, Linking crystallographic model and data quality. Science 336, 1030–1033 (2012). doi: 10.1126/science.1218231; pmid: 22628654
68. M. D. Winn et al., Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235–242 (2011). doi: 10.1107/S0907444910045749; pmid: 21460441
69. G. N. Murshudov, A. A. Vagin, E. J. Dodson, Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240–255 (1997). doi: 10.1107/S0907444996012255; pmid: 15299926
70. G. N. Murshudov et al., REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355–367 (2011). doi: 10.1107/S0907444911001314; pmid: 21460454
71. P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010). doi: 10.1107/S0907444910007493; pmid: 20383002
72. E. Krissinel, K. Henrick, Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr. D Biol. Crystallogr. 60, 2256–2268 (2004). doi: 10.1107/S0907444904026460; pmid: 15572779
73. A. C. Wallace, R. A. Laskowski, J. M. Thornton, LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8, 127–134 (1995). doi: 10.1093/protein/8.2.127; pmid: 7630882
74. G. Canevari et al., Structural insight into maternal embryonic leucine zipper kinase (MELK) conformation and inhibition toward structure-based drug design. Biochemistry 52, 6380–6387 (2013). doi: 10.1021/bi4005864; pmid: 23914841
75. T. G. G. Battye, L. Kontogiannis, O. Johnson, H. R. Powell, A. G. W. Leslie, iMOSFLM: A new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr. D Biol. Crystallogr. 67, 271–281 (2011). doi: 10.1107/S0907444910048675; pmid: 21460445
76. P. Evans, Scaling and assessment of data quality. Acta Crystallogr. D Biol. Crystallogr. 62, 72–82 (2006). doi: 10.1107/S0907444905036693; pmid: 16369096
77. A. J. McCoy et al., Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007). doi: 10.1107/S0021889807021206; pmid: 19461840
78. J. R. Wiśniewski, A. Zougman, N. Nagaraj, M. Mann, Universal sample preparation method for proteome analysis. Nat. Methods 6, 359–362 (2009). doi: 10.1038/nmeth.1322; pmid: 19377485
79. S. Tyanova et al., The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731–740 (2016). doi: 10.1038/nmeth.3901; pmid: 27348712
80. D. Szklarczyk et al., STRING v10: Protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43, D447–D452 (2015). doi: 10.1093/nar/gku1003; pmid: 25352553
81. Z. Wu, A. M. Gholami, B. Kuster, Systematic identification of the HSP90 candidate regulated proteome. Mol. Cell. Proteomics 11, M111.016675 (2012). doi: 10.1074/mcp.M111.016675; pmid: 22337586
82. V. Ermolayev et al., Early recognition of lung cancer by integrin targeted imaging in K-ras mouse model. Int. J. Cancer 137, 1107–1118 (2015). doi: 10.1002/ijc.29372; pmid: 25450481
83. G. Kayser et al., Simultaneous multi-antibody staining in non-small cell lung cancer strengthens diagnostic accuracy especially in small tissue samples. PLOS ONE 8, e56333 (2013). doi: 10.1371/journal.pone.0056333; pmid: 23418554
84. H. Polzer, H. Janke, D. Schmid, W. Hiddemann, K. Spiekermann, Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases. Exp. Hematol. 41, 271–280 (2013). doi: 10.1016/j.exphem.2012.10.016; pmid: 23127761
85. H. Janke et al., Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia. PLOS ONE 9, e89560 (2014). doi: 10.1371/journal. pone.0089560; pmid: 24608088
86. H. Polzer et al., Individualized treatment strategy with small-molecular inhibitors in acute myeloid leukemia with concurrent FLT3-ITD and FLT3-TKD mutation. J. Clin. Case Rep. 5, 622 (2015). doi: 10.4172/2165-7920.1000622
87. B. A. Rabinovich et al., Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc. Natl. Acad. Sci. U.S.A. 105, 14342–14346 (2008). doi: 10.1073/pnas.0804105105; pmid: 18794521
88. N. Terziyska, C. Castro Alves, V. Groiss, K. Schneider, K. Farkasova, M. Ogris, E. Wagner, H. Ehrhardt, R. J. Brentjens, U. zur Stadt, M. Horstmann, L. Quintanilla-Martinez, I. Jeremias, In vivo imaging enables high resolution preclinical trials on patients’ leukemia cells growing in mice. PLOS ONE 7, e52798 (2012). doi: 10.1371/journal.pone.0052798; pmid: 23300782